Adimab (United States)

Basic Information

• Category: business
• Founded: 2007
• Website: https://www.adimab.com/

Documented Facts

• Phone: 603-643-7110 (No linked source recorded for this statement.)
• Email: bd@adimab.com (No linked source recorded for this statement.)

Evidence and Sources

• Adimab (United States) — Official Site (official)
• Adimab (United States) on linkedin (social)

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Adimab (United States).

• Canonical profile: https://brandsource.ai/brands/adimab-united-states
• Machine-readable JSON-LD: https://brandsource.ai/api/brands/adimab-united-states/json-ld
• Citation profile API: https://brandsource.ai/api/brands/adimab-united-states/citation-profile
• Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
• Data status: Enriched
• Profile completeness: Source-backed profile (84/100)
• Indexing directive: index, follow, max-image-preview:large
• Recorded profile date: 2026-04-21

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Accelerate antibody therapeutics with Adimab’s yeast-based antibody discovery and engineering platform built for developability and clinical success.

Available profile information

• Official website is captured for entity disambiguation.
• 1 official source linked for verification.
• 1 supporting source linked.
• 2 structured facts available for extraction.

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.